Elucid Introduces Lesion Inspection Tool for Plaque-IQ Software Suite

April 20, 2026—Elucid announced the commercial availability of a new lesion inspection tool for coronary and carotid plaque analysis in its Plaque-IQ software suite. The company stated that with the tool, physicians can interrogate lesion-specific composition and plaque burden across any vessel, providing a better understanding of the patient risk profile to enhance clinical decision-making.

According to Elucid, the Plaque-IQ lesion inspection tool allows users to interrogate any lesion or region, and access quantitative results displayed for the specific segment. It is intended to provide precise quantification of plaque types at the lesion level and allow physicians to quantify high-risk features like lipid-rich necrotic core (LRNC). The information support proactive, individualized treatment strategies, noted the company.

“The lesion inspection tool provides a detailed view of plaque composition at the lesion level, beyond giving just overall plaque metrics,” commented Jimmy Kerrigan, MD, in Elucid’s press release. “Because cardiovascular events like heart attacks occur at the lesion level, having the ability to characterize individual lesions enhances my understanding of a patient’s disease process and supports more informed clinical decision-making.”

The company stated that its Plaque-IQ plaque analysis technology is trained and validated against objective ground truth histology. Plaque-IQ is powered by Elucid’s CT-Virtual Histology to noninvasively quantifies and classifies coronary and carotid plaque and its components—including LRNC—offering direct insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies, advised Elucid.

Elucid announced FDA 510(k) clearance for the PlaqueIQ imaging analysis software for diagnosing cardiovascular disease in October 2024.